Latest News in the pharma Industry

Research & Development

Chemotherapy as a tablet instead of an intravenous infusion

Chemotherapy as a tablet instead of an intravenous infusion

28 Mar 2017

New production method for solid dispersions of docetaxel and paclitaxel.

Read more 
Encouraging results of Phase IIa study with Evenamide in patients with schizophrenia

Encouraging results of Phase IIa study with Evenamide in patients with schizophrenia

27 Mar 2017

Unique mechanism: glutamate modulation and voltage-gated sodium channel blockade.

Read more 
Eprex marketing authorisation extended to include treatment of symptomatic anaemia

Eprex marketing authorisation extended to include treatment of symptomatic anaemia

27 Mar 2017

French Health Authority ANSM grants approval in the Mutual Recognition Procedure; the relevant health authorities are required to implement the new indication within 30 days.

Read more 
Pfizer receives positive CHMP opinion for Trumenba for prevention of meningococcal group B disease

Pfizer receives positive CHMP opinion for Trumenba for prevention of meningococcal group B disease

27 Mar 2017

Trumenba has been studied in a global clinical development program evaluating the vaccine in adolescents and adults.

Read more 
Uninterrupted Pradaxa showed less major bleeding than warfarin in atrial fibrillation patients

Uninterrupted Pradaxa showed less major bleeding than warfarin in atrial fibrillation patients

20 Mar 2017

Patients studied in the trial were reflective of those undergoing catheter ablation in routine clinical practice, providing highly relevant data to treating physicians.

Read more 
AstraZeneca study shows SGLT-2 inhibitors significantly reduced hospitalizations for heart failure and death

AstraZeneca study shows SGLT-2 inhibitors significantly reduced hospitalizations for heart failure and death

20 Mar 2017

Landmark real-world evidence from an international study of more than 300,000 patients with type-2 diabetes showed treatment with SGLT-2 inhibitors reduced risk of hospitalization for heart failure by 39% and all-cause mortality by 51%.

Read more 
Apogenix presents data on novel Hexavalent TNF receptor agonists

Apogenix presents data on novel Hexavalent TNF receptor agonists

20 Mar 2017

Agonists for GIT, CD27 and CD40 receptors in development for cancer immunotherapy exhibit significant in vitro- and in vivo activities.

Read more 
New analysis shows Novartis Entresto improves glycemic control among heart failure patients with diabetes

New analysis shows Novartis Entresto improves glycemic control among heart failure patients with diabetes

19 Mar 2017

New use of insulin was also reduced by 29% among patients taking Entresto compared to enalapril-treated patients.

Read more 
Dementia Consortium funds Manchester-based team targeting immune system in search for new dementia treatments

Dementia Consortium funds Manchester-based team targeting immune system in search for new dementia treatments

19 Mar 2017

Team led by Dr David Brough awarded £191,757 by public-private initiative driving early-stage drug discovery programmes.

Read more 
Landmark outcomes study shows that Repatha  decreases LDL-C to unprecedented low levels

Landmark outcomes study shows that Repatha decreases LDL-C to unprecedented low levels

17 Mar 2017

Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible wit...

Read more 
FDA approves Novartis' Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer

FDA approves Novartis' Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer

16 Mar 2017

Kisqali plus letrozole showed treatment benefit across all patient subgroups regardless of disease burden or tumour location.

Read more 
Merck's Keytruda receives FDA approval to treat patients with refractory classical Hodgkin lymphoma

Merck's Keytruda receives FDA approval to treat patients with refractory classical Hodgkin lymphoma

15 Mar 2017

Only anti-PD-1 therapy approved for the treatment of patients with difficult-to-treat cHL regardless of prior stem cell transplantation or use of brentuximab vedotin

Read more